Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Ciba-Geigy
|
| gptkbp:activities |
stimulates dopamine receptors
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:legislation
gptkb:1997 gptkb:Australia gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:brand |
Requip
Requip XL |
| gptkbp:clinical_trial |
Phase III
treatment of Parkinson's disease treatment of RLS |
| gptkbp:contraindication |
severe renal impairment
hypersensitivity to ropinirole |
| gptkbp:developed_by |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:dosage_form |
0.25 mg to 24 mg daily
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ropinirole
|
| gptkbp:ingredients |
C16 H20 N2 S
|
| gptkbp:interacts_with |
gptkb:beer
antidepressants antipsychotics CY P1 A2 inhibitors |
| gptkbp:is_atype_of |
N04 B C05
|
| gptkbp:is_available_on |
generic drug
|
| gptkbp:is_monitored_by |
monitor for impulse control disorders
monitor for orthostatic hypotension monitor for sleep attacks |
| gptkbp:is_used_for |
gptkb:psychologist
Restless legs syndrome |
| gptkbp:lifespan |
6 hours
|
| gptkbp:manager |
oral
|
| gptkbp:metabolism |
CY P1 A2
|
| gptkbp:pharmacokinetics |
dopaminergic activity
bioavailability 50% to 60% peak plasma concentration in 1 to 2 hours |
| gptkbp:research_areas |
gptkb:psychologist
sleep disorders movement disorders |
| gptkbp:safety_features |
Category C during pregnancy
|
| gptkbp:scientific_classification |
dopamine agonist
|
| gptkbp:side_effect |
dizziness
fatigue nausea hallucinations |
| gptkbp:symptoms |
increased RLS symptoms
rebound Parkinsonism |
| gptkbp:type_of |
91374-21-9
|